pTau217: Providing critical Alzheimer's diagnosis with key biomarker data
3 October 2024
Break through with focused insight
Learn how Labcorp quickly responded to the global COVID-19 pandemic helping a sponsor reduce their IND program from 12 to 5 months. Labcorp further supported Phase I and II trial work for FDA Emergency Use Authorization.
Latest content neurological biomarker-driven development
Press release
pTau217 Blood Biomarker Test Accelerates Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials.
Info sheet
Biomarker-driven Alzheimer’s therapy development solutions
Neurology
Expedite delivery of your therapies to address neurodegenerative disorders with industry-leading testing and trial support.
Biomarker solution center
Leverage the benefits of a biomarker strategy – including 3x greater probability of successful transition from Phase I to regulatory approval.